预测HIV相关结核风险评分的推导与外部验证:一项队列研究
研究利用博茨瓦纳XPRES试验数据开发了预测HIV感染者中活动性结核的简易临床评分,并在南非三个队列中外部验证。评分≥2分时灵敏度较WHO四症状筛查提高,负预测值也略有提升。该评分有助于优先安排筛查和更安全地推广结核预防治疗。
要点
- 评分纳入男性、WHO结核症状、吸烟史、体温>37.5°C、BMI<18.5及严重贫血。
- 评分≥2分时灵敏度在四个队列中为88%–97%,高于WHO四症状筛查。
- 评分将风险分为低(<2)、中(2–10)、高(>10)三组,高分组结核患病率更高。
核心结论
- 简易临床评分可优先保证灵敏度和负预测值,有助于减少未诊断结核导致的死亡并更安全地推广结核预防治疗。
- 按评分切点区分风险可灵活设计差异化HIV-TB关怀,以最大化利用现有资源。
研究设计与样本
- 利用博茨瓦纳XPRES试验2012至2015年成人HIV门诊入组者数据,采用逻辑回归和随机森林机器学习方法开发简约多变量预后模型。
- 临床评分通过重新缩放最终模型系数得出,使用博茨瓦纳南部XPRES数据开发,北部数据内部验证,并在南非XPHACTOR、TB Fast Track和Gugulethu三个队列中外部验证。
- XPRES入组5418人,其中2771人纳入推导数据集;女性占67%,中位年龄34岁,中位CD4为240 cells/μL,189人(7%)有未诊断的现患结核。
- 外部验证队列XPHACTOR、TBFT和Gugulethu的中位CD4分别为400、73和167 cells/μL,结核患病率分别为5%、10%和18%。
主要发现
- 推导数据集中预测结核并入选评分的因素包括:男性(1分)、≥1个WHO结核症状(7分)、吸烟史(1分)、体温>37.5°C(6分)、BMI<18.5kg/m2(2分)、严重贫血(血红蛋白<8g/dL)(3分)。
- WHO四症状结核筛查在XPRES、XPHACTOR、TBFT和Gugulethu队列中的灵敏度分别为73%、80%、94%和94%,使用临床评分≥2分时分别提高至88%、87%、97%和97%。
- 以临床评分≥2分替代WHO四症状筛查后,负预测值在XPRES、XPHACTOR、TBFT和Gugulethu队列中分别提高1%、0.3%、1.6%和1.7%。
- 按评分分为低(<2)、中(2–10)、高(>10)风险组,最低风险组结核患病率在四个队列中分别为1%、1%、2%和6%,最高风险组分别为33%、22%、26%和32%。
- 临床评分≥2分时,需筛查人数(NNS)从Gugulethu的5.0到XPHACTOR的11.0不等。
关键数值与推荐
- 临床评分总分为各项分数之和:男性1分,≥1个WHO结核症状7分,吸烟史1分,体温>37.5°C 6分,BMI<18.5kg/m2 2分,严重贫血(血红蛋白<8g/dL)3分。
- 评分风险分层:低风险<2分,中风险2–10分,高风险>10分。
- 评分≥2分作为结核筛查阳性阈值时,灵敏度在验证队列中达87%–97%。
临床怎么用
- 在HIV感染者中可采用该简易临床评分替代WHO四症状筛查,以提高结核筛查灵敏度并减少漏诊。
- 评分可用于优先安排结核筛查和预防治疗,高风险者重点排查活动性结核,低风险者可更安全地启动预防治疗。
- 按评分分层设计差异化HIV-TB关怀,有助于在资源有限地区优化资源配置。
局限性
- 该风险评分尚未在资源丰富地区验证。
- 需要在非洲及其他资源受限地区的当代队列中进一步评估和验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Among people living with HIV (PLHIV), more flexible and sensitive tuberculosis (TB) screening tools capable of detecting both symptomatic and subclinical active TB are needed to (1) reduce morbidity and mortality from undiagnosed TB; (2) facilitate scale-up of tuberculosis preventive therapy (TPT) while reducing inappropriate prescription of TPT to PLHIV with subclinical active TB; and (3) allow for differentiated HIV-TB care. METHODS AND FINDINGS: We used Botswana XPRES trial data for adult HIV clinic enrollees collected during 2012 to 2015 to develop a parsimonious multivariable prognostic model for active prevalent TB using both logistic regression and random forest machine learning approaches. A clinical score was derived by rescaling final model coefficients. The clinical score was developed using southern Botswana XPRES data and its accuracy validated internally, using northern Botswana data, and externally using 3 diverse cohorts of antiretroviral therapy (ART)-naive and ART-experienced PLHIV enrolled in XPHACTOR, TB Fast Track (TBFT), and Gugulethu studies from South Africa (SA). Predictive accuracy of the clinical score was compared with the World Health Organization (WHO) 4-symptom TB screen. Among 5,418 XPRES enrollees, 2,771 were included in the derivation dataset; 67% were female, median age was 34 years, median CD4 was 240 cells/μL, 189 (7%) had undiagnosed prevalent TB, and characteristics were similar between internal derivation and validation datasets. Among XPHACTOR, TBFT, and Gugulethu cohorts, median CD4 was 400, 73, and 167 cells/μL, and prevalence of TB was 5%, 10%, and 18%, respectively. Factors predictive of TB in the derivation dataset and selected for the clinical score included male sex (1 point), ≥1 WHO TB symptom (7 points), smoking history (1 point), temperature >37.5°C (6 points), body mass index (BMI) <18.5kg/m2 (2 points), and severe anemia (hemoglobin <8g/dL) (3 points). Sensitivity using WHO 4-symptom TB screen was 73%, 80%, 94%, and 94% in XPRES, XPHACTOR, TBFT, and Gugulethu cohorts, respectively, but increased to 88%, 87%, 97%, and 97%, when a clinical score of ≥2 was used. Negative predictive value (NPV) also increased 1%, 0.3%, 1.6%, and 1.7% in XPRES, XPHACTOR, TBFT, and Gugulethu cohorts, respectively, when the clinical score of ≥2 replaced WHO 4-symptom TB screen. Categorizing risk scores into low (<2), moderate (2 to 10), and high-risk categories (>10) yielded TB prevalence of 1%, 1%, 2%, and 6% in the lowest risk group and 33%, 22%, 26%, and 32% in the highest risk group for XPRES, XPHACTOR, TBFT, and Gugulethu cohorts, respectively. At clinical score ≥2, the number needed to screen (NNS) ranged from 5.0 in Gugulethu to 11.0 in XPHACTOR. Limitations include that the risk score has not been validated in resource-rich settings and needs further evaluation and validation in contemporary cohorts in Africa and other resource-constrained settings. CONCLUSIONS: The simple and feasible clinical score allowed for prioritization of sensitivity and NPV, which could facilitate reductions in mortality from undiagnosed TB and safer administration of TPT during proposed global scale-up efforts. Differentiation of risk by clinical score cutoff allows flexibility in designing differentiated HIV-TB care to maximize impact of available resources.
引用
- Auld AF, Kerkhoff AD, Hanifa Y, et al. Derivation and external validation of a risk score for predicting HIV-associated tuberculosis to support case finding and preventive therapy scale-up: A cohort study. PLoS Med. 2021. PMID: 34491987. doi:10.1371/journal.pmed.1003739
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。